GET DAILY SIGNALSWhy Is Immutep Limited (IMMP) Stock Down -7.89% Today?
Key Takeaways
- IMMP fell 7.89% to about $3.50, down $0.30 from the prior session's close of $3.80.
- The decline reflects profit-taking after a sharp two-day rally driven by positive Phase I data for its IMP761 autoimmune candidate.
- A "sell-the-news" dynamic took hold as investors digested that the data came from healthy volunteers, not patients, with next results still months away.
- The pullback diverged from broader equities, with Australia's S&P/ASX 200 trading higher during the same session.
- Traders are now watching the multiple ascending dose (MAD) results expected in the first half of 2027 and the company's November 27 annual general meeting.
- For more detail, explore Immutep's Price Targets, Earnings, and Forecast pages to track analyst views and upcoming catalysts.
- Discover how AI-driven strategies are positioning across the market by exploring Trending AI Robots.
Opening Summary
Immutep Limited (IMMP) is a clinical-stage Australian biotechnology company pioneering immunotherapies built around Lymphocyte Activation Gene-3 (LAG-3), targeting both cancer and autoimmune diseases. Its American Depositary Receipts trade on Nasdaq, while its ordinary shares list on the Australian Securities Exchange as IMM. In today's session, IMMP shares pulled back roughly 7.89%, falling from a prior close of $3.80 to about $3.50. The move unwound a portion of the stock's steep two-day advance as investors booked gains following a burst of positive clinical news.
Profit-Taking After a Clinical-News Rally
The most immediate driver behind the decline was a classic "buy the rumor, sell the news" reaction. IMMP shares had surged more than 24% on November 6 and climbed another 13% on November 9, lifting the ADR from around $2.69 to $3.80 in just two sessions. The catalyst for that rally was a late-breaking abstract presented at the American College of Rheumatology's ACR Convergence 2026 conference, which detailed statistically significant, exposure-dependent suppression of T-cell-driven immune responses in a Phase I study of IMP761, the company's first-in-class LAG-3 agonist antibody.
With that enthusiasm already priced in, today's session saw traders locking in gains, a common pattern in biotechnology after sharp, news-driven spikes. The magnitude of the prior advance made a near-8% retracement a relatively orderly giveback rather than a breakdown in the underlying thesis.
Phase I Data Scope and Timeline
A secondary factor weighing on sentiment was the nature of the data itself. While the IMP761 results were viewed positively, they were generated in 60 healthy volunteers using a keyhole limpet hemocyanin (KLH) challenge model—not in patients with autoimmune disease. Investors recognizing that efficacy in actual patients remains unproven took a more measured view. The multiple ascending dose portion of the study is still ongoing, and the company has said results from that segment are not expected until the first half of 2027, leaving a lengthy gap before the next major readout.
This longer-than-usual catalyst gap can prompt near-term holders to rotate out of a name that has already delivered a substantial short-term pop, particularly in a speculative, cash-burning clinical-stage biotech.
Market Context and Trading Activity
The pullback occurred against a backdrop of broader market strength. Australia's S&P/ASX 200 traded higher by more than 1% during the same period, and the company's ASX-listed shares also fell roughly 7.7%, indicating that the move was company-specific rather than a reflection of broad risk-off sentiment. Trading volume in IMMP ADRs had been running well above the stock's average over the prior two sessions, consistent with elevated participation around the ACR data release.
From a technical standpoint, the stock remains well above its recent low of $2.66 but has now relinquished a portion of the gains that briefly carried it above the $3.90 level intraday. The retreat keeps IMMP in the lower single digits, where it has traded since a brutal March 2026 selloff tied to the discontinuation of its TACTI-004 Phase III lung cancer trial.
What Comes Next for IMMP
Looking ahead, investors will focus on several milestones. The completion and readout of the IMP761 multiple ascending dose portion, anticipated in the first half of 2027, is the nearest major clinical catalyst and will help determine dosing for a potential Phase II study. The company's annual general meeting on November 27 is also in view, where management is expected to provide further updates on its root-cause analysis of the failed TACTI-004 trial and its narrower oncology strategy centered on head and neck cancer and soft tissue sarcoma.
Risks remain significant. The company is pre-revenue, continues to report widening net losses, and faces an ongoing securities class action related to disclosures around TACTI-004. Any new safety signal in the ongoing dosing study, or setbacks in its refined efti development plan, could pressure the shares further. Conversely, continued positive data from IMP761 and progress toward a registrational path would likely support the stock.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a library of hundreds of strategies covering thousands of tickers. Only the strongest performers under current market conditions are featured, with bots varying by strategy type, timeframe, performance metrics, and the symbols they trade. Exploring the page can help traders identify systematic approaches that are adapting to today's evolving market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMMP in +41.26% Uptrend, rising for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IMMP advanced for three days, in 208 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMMP's RSI Oscillator exited the oversold zone, 21 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMMP as a result. In 69 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for IMMP just turned positive on October 20, 2026. Looking at past instances where IMMP's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
IMMP broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMMP entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. IMMP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.999) is normal, around the industry mean (3.498). P/E Ratio (-0.310) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of anti-cancer therapeutics
Industry Biotechnology
Advertisement